OnKure Therapeutics (NASDAQ:OKUR) Raised to Strong-Buy at Leerink Partnrs

OnKure Therapeutics (NASDAQ:OKUR) was upgraded by equities research analysts at Leerink Partnrs to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

Several other equities analysts have also issued reports on the company. Lifesci Capital upgraded OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, October 10th. Oppenheimer assumed coverage on shares of OnKure Therapeutics in a research note on Thursday, October 10th. They issued an “outperform” rating and a $35.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of OnKure Therapeutics in a research report on Friday, November 8th. Finally, Leerink Partners assumed coverage on OnKure Therapeutics in a research note on Thursday. They issued an “outperform” rating and a $33.00 target price on the stock. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, OnKure Therapeutics has an average rating of “Buy” and a consensus target price of $36.00.

OnKure Therapeutics Trading Down 0.3 %

Shares of OnKure Therapeutics stock opened at $14.16 on Thursday. OnKure Therapeutics has a 1 year low of $9.80 and a 1 year high of $77.60. The company has a market capitalization of $47.34 million, a price-to-earnings ratio of -1.16 and a beta of 0.14. The company’s 50 day moving average is $16.77.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.13). Analysts anticipate that OnKure Therapeutics will post -4.21 EPS for the current year.

About OnKure Therapeutics

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.